Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
Varga C, Robinson M, Gupta V, Hofmeister C, Nooka A, Kaufman J, Dhodapkar M, Lonial S, Borden S, Ferreri C, Paul B, Atrash S, Bhutani M, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes. Blood 2024, 144: 4702-4702. DOI: 10.1182/blood-2024-204388.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaCD34+ cells/kgStem cell collectionStem cell yieldLevine Cancer InstituteNewly diagnosed multiple myeloma patientsStem cell mobilizationCD34+ cellsInduction therapyCell collectionG-CSFNo significant differenceDose of G-CSFISS stage III diseaseTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCancer InstituteHigh-risk cytogeneticsMedian patient ageMRD-negative statusStage III diseaseStem cell harvestWinship Cancer InstituteSignificant differenceCharacterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Gu L, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 3780. DOI: 10.1182/blood-2024-211474.Peer-Reviewed Original ResearchNewly diagnosed myelomaProgression free survivalInternational Myeloma Working GroupD-RVdEarly progressionData cutoffMedian followMedian time to progressionYear progression free survivalNewly diagnosed multiple myelomaHigh riskEstimate 3-year survivalPresence of del(17pR-ISS-3Time to progressionEffective induction regimenFirst-line therapyStem cell transplantationDepth of responseDocumented disease progressionCohort of patientsAge of diagnosisLong-term outcomesAlternative treatment approachesMedian OSImpact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.Peer-Reviewed Original ResearchNewly diagnosed myelomaD-RVdBlack patientsStatistically significant differenceInduction therapyR-ISSOverall survivalMedian ageInternational Myeloma Working Group Uniform Response CriteriaWhite patientsImproved depth of responsePresence of extramedullary diseaseNewly diagnosed multiple myelomaResponse rateMedian overall survivalR-ISS-3Effective induction regimenHigh-risk featuresStem cell transplantationDepth of responseSignificant differenceClinical trial findingsStandard of careHigh-risk classificationMedian PFSP-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients
Joseph N, Pruitt R, Gupta V, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Kaufman J. P-342 Impact of AchievingDOI: 10.1016/s2152-2650(24)02244-4. Peer-Reviewed Original ResearchStem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience
Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaLevine Cancer InstituteStem cell yieldNewly diagnosed multiple myeloma patientsStem cell collectionStem cell mobilizationInduction therapyG-CSFDose of G-CSFTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCell collectionCancer InstituteCD34+ cells/kgMRD-negative statusMedian patient ageStem cell harvestWinship Cancer InstituteCD34+ cellsGrowth colony-stimulating factorColony-stimulating factorNDMM patientsGoal dosePatient age